search
Back to results

Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Poorly Healed Wounds of Postoperative Incision

Primary Purpose

MSCs-PFs in Treating Poorly Healed Wounds of Postoperative Incision

Status
Unknown status
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
The pleiotropic factor derived from mesenchymal stem cells
Sponsored by
Chinese PLA General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for MSCs-PFs in Treating Poorly Healed Wounds of Postoperative Incision

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Wound size <10X10cm2, the wound base only involves subcutaneous and muscle tissue;
  2. Underwent surgical treatment, all incisions were type I, and the incisions healed poorly and delayed healing after 1 week;
  3. There is inflammatory reaction at the incision, but no clear indication of infection, or severe infection of the incision.After debridement and dressing change, the infection is controlled and the fresh granulation period is entered
  4. Men or women older than 17 years old and younger than 75 years old;
  5. Psychologically stable, able to complete the test process.

Exclusion Criteria:

  1. Wound size>10X10cm2, the wound base is as deep as the chest and abdominal cavity, causing infection or osteomyelitis in the chest and abdominal cavity;
  2. Surgical incision with purulent infection, local purulent secretions can be seen;
  3. Those with obvious body temperature and white blood cell elevation, local purulent secretions have positive bacterial culture;
  4. Patients with diabetes;
  5. Glucocorticoid users;
  6. Patients with immune dermatosis;
  7. Neoplastic wounds, such as wounds after skin cancer resection, or skin wounds caused by tumor invasion;
  8. Psycho-psychological disorders and poor compliance.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    No Intervention

    Experimental

    Arm Label

    control group

    experimental group

    Arm Description

    No intervention

    The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2)

    Outcomes

    Primary Outcome Measures

    Wound healing time and healing rate
    Judgment criteria for incision recovery (4 weeks after treatment): Cure: the patient's incision is completely or basically healed, and the surrounding skin returns to normal; markedly effective: the patient's incision is recovered> 1/2, and the surrounding skin returns to normal; effective: the patient's incision is recovered <1 /2, and the surrounding skin returned to normal; invalid: the patient's incision had no obvious changes, and the surrounding skin color had no obvious improvement.

    Secondary Outcome Measures

    Full Information

    First Posted
    August 30, 2020
    Last Updated
    September 7, 2020
    Sponsor
    Chinese PLA General Hospital
    Collaborators
    Gansu Provincial Maternal and Child Health Care Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04538885
    Brief Title
    Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Poorly Healed Wounds of Postoperative Incision
    Official Title
    Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Poorly Healed Wounds of Postoperative Incision
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2020
    Overall Recruitment Status
    Unknown status
    Study Start Date
    September 10, 2020 (Anticipated)
    Primary Completion Date
    March 31, 2021 (Anticipated)
    Study Completion Date
    May 30, 2021 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Chinese PLA General Hospital
    Collaborators
    Gansu Provincial Maternal and Child Health Care Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    Poor incision healing is a common complication after abdominal surgery, mainly manifested as incision dehiscence, subcutaneous fat liquefaction, malnutrition, and incision infection. Poor healing of the incision will increase the patient's pain and prolong the patient's hospital stay, and the choice of wound treatment is closely related to the wound healing effect. Mesenchymal stem cells mainly rely on paracrine effects to exert their therapeutic effects and obtain better therapeutic effects in wound healing. Here, the pleiotropic factors secreted from mesenchymal stem cells (MSCs-PFs) will be used to treat patients with poor healing after surgery to evaluate its effectiveness and safety.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    MSCs-PFs in Treating Poorly Healed Wounds of Postoperative Incision

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    50 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    control group
    Arm Type
    No Intervention
    Arm Description
    No intervention
    Arm Title
    experimental group
    Arm Type
    Experimental
    Arm Description
    The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2)
    Intervention Type
    Biological
    Intervention Name(s)
    The pleiotropic factor derived from mesenchymal stem cells
    Intervention Description
    The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2), and then the wound was covered with a foam dressing; the dressing was changed every 3 days to reach clinical healing as the end of the trial.
    Primary Outcome Measure Information:
    Title
    Wound healing time and healing rate
    Description
    Judgment criteria for incision recovery (4 weeks after treatment): Cure: the patient's incision is completely or basically healed, and the surrounding skin returns to normal; markedly effective: the patient's incision is recovered> 1/2, and the surrounding skin returns to normal; effective: the patient's incision is recovered <1 /2, and the surrounding skin returned to normal; invalid: the patient's incision had no obvious changes, and the surrounding skin color had no obvious improvement.
    Time Frame
    1 month

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Wound size <10X10cm2, the wound base only involves subcutaneous and muscle tissue; Underwent surgical treatment, all incisions were type I, and the incisions healed poorly and delayed healing after 1 week; There is inflammatory reaction at the incision, but no clear indication of infection, or severe infection of the incision.After debridement and dressing change, the infection is controlled and the fresh granulation period is entered Men or women older than 17 years old and younger than 75 years old; Psychologically stable, able to complete the test process. Exclusion Criteria: Wound size>10X10cm2, the wound base is as deep as the chest and abdominal cavity, causing infection or osteomyelitis in the chest and abdominal cavity; Surgical incision with purulent infection, local purulent secretions can be seen; Those with obvious body temperature and white blood cell elevation, local purulent secretions have positive bacterial culture; Patients with diabetes; Glucocorticoid users; Patients with immune dermatosis; Neoplastic wounds, such as wounds after skin cancer resection, or skin wounds caused by tumor invasion; Psycho-psychological disorders and poor compliance.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Meirong Li, doctor
    Phone
    010-66936345
    Email
    meirong811225@126.com

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided
    IPD Sharing Plan Description
    If any researcher needs it, you can apply to us

    Learn more about this trial

    Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Poorly Healed Wounds of Postoperative Incision

    We'll reach out to this number within 24 hrs